Medical treatment of benign prostatic hyperplasia: Physician and patient preferences and satisfaction

International Journal of Clinical Practice

Volumn 64, Issue 10, 2010, Pages 1425-1435

  Emberton, M ^a  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; TAMSULOSIN;

DISEASE COURSE; EJACULATION DISORDER; ERECTILE DYSFUNCTION; HUMAN; IMPOTENCE; INCIDENCE; LIBIDO; MEDLINE; MICTURITION; MIXED INCONTINENCE; ORGAN SIZE; PATIENT SATISFACTION; PHYSICIAN; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; REVIEW; SYSTEMATIC REVIEW; TRANSURETHRAL RESECTION; VISUAL ANALOG SCALE;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; AGED; ATTITUDE OF HEALTH PERSONNEL; CLINICAL TRIALS AS TOPIC; HUMANS; MALE; MIDDLE AGED; PATIENT PREFERENCE; PATIENT SATISFACTION; PHYSICIAN-PATIENT RELATIONS; PROSTATIC HYPERPLASIA; QUESTIONNAIRES; TRANSURETHRAL RESECTION OF PROSTATE; UROLOGY; WATCHFUL WAITING;

EID: 77955802613     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02463.x     Document Type: Review

References (31)

1. Hong SJ, Rayford W, Valiquette L, Emberton M. The importance of patient perception in the clinical assessment of benign prostatic hyperplasia and its management. BJU Int 2005 95 : 15 9.
2. American Urological Association. Guideline on the Management of Benign Prostatic Hyperplasia (BPH).
3. Emberton M, Marberger M, de la Rosette J. Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: The Prostate Research on Behaviour and Education (PROBE) Survey. Int J Clin Pract 2008 62 : 18 26.
4. Barkin J, Roehrborn CG, Siami P et al. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe BPH: 2-year data from the CombAT trial. BJU Int 2009 103 : 919 26.
5. Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 2004 46 : 547 54.
6. Vallancien G, Emberton M, Alcaraz A et al. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice. BJU Int 2008 101 : 847 52.
7. Emberton M, Elhilali M, Matzkin H et al. Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily. Urology 2005 66 : 316 22.
8. McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003 349 : 2387 98.
9. Roehrborn CG. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. BJU Int 2006 97 : 734 41.
10. Persson K, Pandita RK, Spitsbergen JM et al. Spinal and peripheral mechanisms contributing to hyperactive voiding in spontaneously hypertensive rats. Am J Physiol 1998 275 : R1366 73.
11. Schwinn DA. The role of alpha1-adrenergic receptor subtypes in lower urinary tract symptoms. BJU Int 2001 88 : 27 34, discussion 49-50.
12. Debruyne F, Barkin J, van Erps P et al. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004 46 : 488 94.
13. Roehrborn CG, Boyle P, Nickel JC et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002 60 : 434 41.
14. Roehrborn CG, Lukkarinen O, Mark S et al. Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies. BJU Int 2005 96 : 572 7.
15. Roehrborn CG, Siami P, Barkin J et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008 179 : 616 21.
16. Watson V, Ryan M, Brown CT et al. Eliciting preferences for drug treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol 2004 172 : 2321 5.
17. Llewellyn-Thomas HA, Williams JI, Levy L, Naylor CD. Using a trade-off technique to assess patients' treatment preferences for benign prostatic hyperplasia. Med Decis Making 1996 16 : 262 82.
18. Piercy GB, Deber R, Trachtenberg J et al. Impact of a shared decision-making program on patients with benign prostatic hyperplasia. Urology 1999 53 : 913 20.
19. Kaplan S, Naslund M. Public, patient, and professional attitudes towards the diagnosis and treatment of enlarged prostate: a landmark national US survey. Int J Clin Pract 2006 60 : 1157 65.
20. Stoevelaar HJ, Van De Beek C, Casparie AF et al. Treatment choice for benign prostatic hyperplasia: a matter of urologist preference? J Urol 1999 161 : 133 8.
21. Seftel A, Rosen R, Kuritzky L. Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications. Int J Impot Res 2007 19 : 386 92.
22. Kaplan SA, Olsson CA. Patient satisfaction with finasteride in the treatment of symptomatic benign prostatic hyperplasia. Clin Ther 1996 18 : 73 83.
23. Desgrandchamps F, Droupy S, Irani J et al. Effect of dutasteride on the symptoms of benign prostatic hyperplasia, and patient quality of life and discomfort, in clinical practice. BJU Int 2006 98 : 83 8.
24. Cam K, Akman Y, Kayikci A et al. Short-term subjective efficacy of doxazosin in predicting probability of prostatectomy in the management of benign prostatic hyperplasia in patients with severe symptoms. Int J Urol 2003 10 : 582 6.
25. Hareendran A, Abraham L. Using a treatment satisfaction measure in an early trial to inform the evaluation of a new treatment for benign prostatic hyperplasia. Value Health 2005 8 : S35 40.
26. Siami P, Roehrborn CG, Barkin J et al. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design. Contemp Clin Trials 2007 28 : 770 9.
27. Black L, Grove A, Morrell B. The psychometric validation of a US English satisfaction measure for patients with benign prostatic hyperplasia and lower urinary tract symptoms. Health Qual Life Outcomes 2009 7 : 55.
28. Boyle P, Roehrborn C, Harkaway R et al. 5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery. Eur Urol 2004 45 : 620 6, discussion 6-7.
29. Marberger M, Harkaway R, de la Rosette J. Optimising the medical management of benign prostatic hyperplasia. Eur Urol 2004 45 : 411 9.
30. Barkin J, Guimaraes M, Jacobi G et al. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol 2003 44 : 461 6.
31. Rosen R, Altwein J, Boyle P et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003 44 : 637 49.